157 related articles for article (PubMed ID: 34368121)
1. NAP1L1 Functions as a Tumor Promoter
Zhang YW; Chen Q; Li B; Li HY; Zhao XK; Xiao YY; Liu S; Zuo S
Front Cell Dev Biol; 2021; 9():659680. PubMed ID: 34368121
[TBL] [Abstract][Full Text] [Related]
2. NAP1L1 targeting suppresses the proliferation of nasopharyngeal carcinoma.
Liu Y; Li X; Zhang Y; Tang Y; Fang W; Liu X; Liu Z
Biomed Pharmacother; 2021 Nov; 143():112096. PubMed ID: 34563951
[TBL] [Abstract][Full Text] [Related]
3. NAP1L1 interacts with hepatoma-derived growth factor to recruit c-Jun inducing breast cancer growth.
Liu S; Zhang Y; Cui S; Song D; Li B; Chen Q; Yao G; Gong B
Cancer Cell Int; 2021 Nov; 21(1):605. PubMed ID: 34774047
[TBL] [Abstract][Full Text] [Related]
4. NAP1L1 promotes tumor proliferation through HDGF/C-JUN signaling in ovarian cancer.
Xiaohua Zhu ; Xie Y; Huang W; Chen Z; Guo S
BMC Cancer; 2022 Mar; 22(1):339. PubMed ID: 35351053
[TBL] [Abstract][Full Text] [Related]
5. NAP1L1 promotes proliferation and chemoresistance in glioma by inducing CCND1/CDK4/CDK6 expression through its interaction with HDGF and activation of c-Jun.
Chen Z; Xie Y; Luo H; Song Y; Que T; Hu R; Huang H; Luo K; Li C; Qin C; Zheng C; Fang W; Liu L; Long H; Luo Q
Aging (Albany NY); 2021 Dec; 13(24):26180-26200. PubMed ID: 34959221
[TBL] [Abstract][Full Text] [Related]
6. NAP1L1 Functions as a Novel Prognostic Biomarker Associated With Macrophages and Promotes Tumor Progression by Influencing the Wnt/β-Catenin Pathway in Hepatocellular Carcinoma.
Shen B; Zhu W; Liu X; Jiang J
Front Genet; 2022; 13():876253. PubMed ID: 35664324
[TBL] [Abstract][Full Text] [Related]
7. NAP1L1 is a prognostic biomarker and contribute to doxorubicin chemotherapy resistance in human hepatocellular carcinoma.
Le Y; Kan A; Li QJ; He MK; Chen HL; Shi M
Cancer Cell Int; 2019; 19():228. PubMed ID: 31516385
[TBL] [Abstract][Full Text] [Related]
8. NAP1L1 promotes the growth of colon cancer by activating HDGF/DDX5.
Liang X; Tang Z; Zhang Y; Sun Y; Wang J
Acta Biochim Biophys Sin (Shanghai); 2022 Sep; 54(9):1234-1243. PubMed ID: 36148951
[TBL] [Abstract][Full Text] [Related]
9. Hepatoma-derived growth factor/nucleolin axis as a novel oncogenic pathway in liver carcinogenesis.
Chen SC; Hu TH; Huang CC; Kung ML; Chu TH; Yi LN; Huang ST; Chan HH; Chuang JH; Liu LF; Wu HC; Wu DC; Chang MC; Tai MH
Oncotarget; 2015 Jun; 6(18):16253-70. PubMed ID: 25938538
[TBL] [Abstract][Full Text] [Related]
10. HDGF-related protein-3 is required for anchorage-independent survival and chemoresistance in hepatocellular carcinomas.
Xiao Q; Qu K; Wang C; Kong Y; Liu C; Jiang D; Saiyin H; Jia F; Ni C; Chen T; Zhang Y; Zhang P; Qin W; Sun Q; Wang H; Yi Q; Liu J; Huang H; Yu L
Gut; 2013 Mar; 62(3):440-51. PubMed ID: 22490522
[TBL] [Abstract][Full Text] [Related]
11. Expression of hepatoma-derived growth factor in hepatocellular carcinoma.
Hu TH; Huang CC; Liu LF; Lin PR; Liu SY; Chang HW; Changchien CS; Lee CM; Chuang JH; Tai MH
Cancer; 2003 Oct; 98(7):1444-56. PubMed ID: 14508832
[TBL] [Abstract][Full Text] [Related]
12. Hepatoma-derived growth factor promotes growth and metastasis of hepatocellular carcinoma cells.
Yang GY; Zhang AQ; Wang J; Li CH; Wang XQ; Pan K; Zhou C; Dong JH
Cell Biochem Funct; 2016 Jun; 34(4):274-85. PubMed ID: 27273265
[TBL] [Abstract][Full Text] [Related]
13. Hepatoma-Derived Growth Factor: Its Possible Involvement in the Progression of Hepatocellular Carcinoma.
Enomoto H; Nakamura H; Liu W; Nishiguchi S
Int J Mol Sci; 2015 Jun; 16(6):14086-97. PubMed ID: 26101867
[TBL] [Abstract][Full Text] [Related]
14. NAP1L1 regulates BIRC2 ubiquitination modification via E3 ubiquitin ligase UBR4 and hence determines hepatocellular carcinoma progression.
Zhang SL; Zhang SJ; Li L; Zhang YW; Wang Z; Wang L; Lu JY; Chen TX; Zuo S
Cell Death Discov; 2024 Mar; 10(1):154. PubMed ID: 38538582
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-214 downregulation contributes to tumor angiogenesis by inducing secretion of the hepatoma-derived growth factor in human hepatoma.
Shih TC; Tien YJ; Wen CJ; Yeh TS; Yu MC; Huang CH; Lee YS; Yen TC; Hsieh SY
J Hepatol; 2012 Sep; 57(3):584-91. PubMed ID: 22613005
[TBL] [Abstract][Full Text] [Related]
16. Role of hepatoma-derived growth factor in promoting de novo lipogenesis and tumorigenesis in hepatocellular carcinoma.
Min X; Wen J; Zhao L; Wang K; Li Q; Huang G; Liu J; Zhao X
Mol Oncol; 2018 Sep; 12(9):1480-1497. PubMed ID: 30004626
[TBL] [Abstract][Full Text] [Related]
17. Positive feedback loop of FAM83A/PI3K/AKT/c-Jun induces migration, invasion and metastasis in hepatocellular carcinoma.
Liu C; Peng X; Li Y; Liu S; Hou R; Zhang Y; Zuo S; Liu Z; Luo R; Li L; Fang W
Biomed Pharmacother; 2020 Mar; 123():109780. PubMed ID: 31901550
[TBL] [Abstract][Full Text] [Related]
18. MiRNA-610 acts as a tumour suppressor to depress the cisplatin resistance in hepatocellular carcinoma through targeted silencing of hepatoma-derived growth factor.
Xu Y; Wang H; Gao W
Arch Med Sci; 2020; 16(6):1394-1401. PubMed ID: 33224339
[TBL] [Abstract][Full Text] [Related]
19. Long non‑coding RNA MKLN1‑AS aggravates hepatocellular carcinoma progression by functioning as a molecular sponge for miR‑654‑3p, thereby promoting hepatoma‑derived growth factor expression.
Gao W; Chen X; Chi W; Xue M
Int J Mol Med; 2020 Nov; 46(5):1743-1754. PubMed ID: 33000222
[TBL] [Abstract][Full Text] [Related]
20. BUB1B promotes hepatocellular carcinoma progression via activation of the mTORC1 signaling pathway.
Qiu J; Zhang S; Wang P; Wang H; Sha B; Peng H; Ju Z; Rao J; Lu L
Cancer Med; 2020 Nov; 9(21):8159-8172. PubMed ID: 32977361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
